drugset / Trial / NCT01244009
A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will investigate the efficacy and safety of MK-4827 in participants with relapsed mantle cell lymphoma (MCL) and in a subset of participants with inactivation of the Ataxia-Telangiectasia Mutated (ATM) gene.
Timeline
- Start
- 2010-12
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | — | Oral |